Communiqués TransCode Therapeutics, Inc.

Actions

RNAZ

US89357L5012

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 21/08/2026			Varia. 5j.	Varia. 1 janv.
2,870 ^USD	-3,37%		-12,50%	-57,98%

14/08	TransCode Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
18/06	Transcript : TransCode Therapeutics, Inc. - Special Call

Communiqués

07/08	Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV	AQ
03/03	TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients	PR
23/02	TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development	PR
05/02	TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138	PR
06/01	TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma	PR
22/12	TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors	PR
11/12	TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial	PR
17/11	TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer	PR
14/10/25	TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO	PR
09/10/25	TransCode Therapeutics announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences	AQ
23/05/25	TransCode Therapeutics : May 2025 Investor Presentation	PU
08/05/25	TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported	PR
05/05/25	TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split	PR
02/05/25	TransCode Therapeutics Announces 1-for-28 Reverse Stock Split	PR
01/05/25	TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer	PR
21/04/25	TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting	PR
27/03/25	TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138	PR
24/03/25	TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	PR
13/03/25	TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial	PR
25/02/25	TransCode Therapeutics, Inc. Announces Results of Special Meeting	PR
06/02/25	TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial	PR
04/02/25	TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting	PR
14/01/25	TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial	PR
07/01/25	Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements	PR
20/12/24	TransCode Therapeutics : Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX MC138 Clinical Trial Form 8 K	PU